Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
Status:
Withdrawn
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a proof of concept, single center study for the donation of HCV-positive hearts to
HCV negative recipient patients, with preemptive, interventional treatment with 12-16 weeks
of grazoprevir and elbasvir (with or without ribavirin) to prevent HCV transmission upon
transplantation.